Core Insights - Vivoryon Therapeutics N.V. will report its Q3 2025 financial results and operational progress on December 4, 2025 [1] - The company focuses on developing small molecule medicines for inflammatory and fibrotic disorders, particularly kidney diseases [3] Financial Results Announcement - The financial results for the period ending September 30, 2025, will be published on December 4, 2025 [1] - A conference call and webcast will be held to discuss these results, open to the public [1][2] Conference Call Details - The conference call is scheduled for December 4, 2025, at 3:00 pm CET / 9:00 am EST [2] - Participants can join via phone or webcast, with pre-registration recommended for phone access [2] Company Overview - Vivoryon is a clinical stage biotechnology company focused on innovative small molecule-based medicines for treating inflammatory and fibrotic disorders of the kidney [3] - The company's leading program, varoglutamstat, is a first-in-class orally available QPCT/L inhibitor aimed at treating diabetic kidney disease [3]

Core Insights - Vivoryon Therapeutics N.V. presented Phase 2 clinical study data for varoglutamstat at the ASN Kidney Week 2025, highlighting its potential to stabilize and improve kidney function in patients [2][3][7] Group 1: Clinical Study Findings - The poster presented data from the VIVIAD Phase 2B randomized clinical trial, showing a significant correlation between the reduction of the anti-inflammatory biomarker pE-CCL2 and improved kidney function as measured by eGFR [4][6] - A decrease in pE-CCL2 levels at week 48 was statistically correlated with a positive eGFR slope over time, indicating the potential effectiveness of varoglutamstat in treating kidney disease [4][5] Group 2: Company Strategy and Future Plans - Vivoryon plans to confirm the compelling data from its Phase 2 studies by conducting a dedicated Phase 2B clinical study in patients with advanced diabetic kidney disease, contingent on additional funding and partnerships [5][8] - The company emphasizes the importance of its innovative approach to treating diabetic kidney disease and other chronic kidney disorders through the inhibition of glutaminyl-cyclases with varoglutamstat [5][8]

Core Insights - Vivoryon Therapeutics N.V. is a clinical stage biotechnology company focused on developing small molecule medicines for inflammatory and fibrotic disorders, particularly kidney diseases [4] Conference Participation - The company will present at the American Society of Nephrology Kidney Week 2025 from November 5 to 9, 2025, in Houston, TX, USA, with a presentation titled "Correlation of eGFR and pE-CCL2 in Older Adult Patients Treated with Varoglutamstat: Data from VIVIAD, a Phase 2B Randomized Clinical Trial" scheduled for November 6 [2] - Additionally, the company will participate in 1x1 meetings at the Jefferies Global Healthcare Conference from November 18 to 20, 2025, in London, UK [3] - The company will also attend the Deutsches Eigenkapitalforum from November 24 to 26, 2025, in Frankfurt, Germany [3] Product Development - Vivoryon's leading program, varoglutamstat, is a proprietary, first-in-class orally available QPCT/L inhibitor being evaluated for the treatment of diabetic kidney disease [4]

Core Viewpoint - Vivoryon Therapeutics N.V. has successfully completed a private placement, raising EUR 5.1 million to support the development of its lead candidate, varoglutamstat, for chronic kidney disease [2][3][6]. Financial Summary - The private placement involved the issuance of 3,380,500 new ordinary shares at an offering price of EUR 1.50 per share, resulting in gross proceeds of EUR 5.1 million [4]. - The new shares represent 12.9% of Vivoryon's existing issued share capital, increasing the total number of shares outstanding to 29,614,337 and the share capital to EUR 296,143.37 [4][8]. Use of Proceeds - The funds raised will be utilized for the ongoing clinical development of varoglutamstat, securing a strategic partnership, and potentially additional funding for a planned Phase 2 study in diabetic kidney disease [6][8]. - The company anticipates that the existing cash, including the proceeds from this placement, will be sufficient to fund operations into Q3 2026 [7][8]. Market Position and Strategy - Vivoryon is focused on developing small molecule medicines for inflammatory and fibrotic disorders, particularly targeting kidney diseases [3][9]. - The successful financing reflects investor confidence in the company's strategy and its program for varoglutamstat [6].

Core Insights - Vivoryon Therapeutics N.V. reported financial results for H1 2025, highlighting progress in its clinical programs, particularly with varoglutamstat for kidney diseases [2][3][15] Financial Performance - Revenues for the six months ended June 30, 2025, were zero, consistent with the same period in 2024 [15] - Research and development expenses decreased by EUR 7.5 million to EUR 2.8 million compared to EUR 10.3 million in H1 2024, primarily due to reduced clinical development costs [16] - General and administrative expenses were EUR 2.8 million, down from EUR 3.5 million in H1 2024, attributed to lower personnel and consulting costs [17] - The net loss for H1 2025 was EUR 5.5 million, significantly reduced from EUR 13.6 million in H1 2024 [17] - Cash and cash equivalents stood at EUR 4.8 million as of June 30, 2025, down from EUR 9.4 million at the end of 2024 [18] Clinical Developments - The company has made significant advancements in the clinical program for varoglutamstat, including a new patent in the U.S. extending exclusivity through 2044 [3][6] - Compelling data from the VIVIAD and VIVA-MIND studies were presented, showing that varoglutamstat significantly improved eGFR kidney function [7][8] - Pre-clinical data indicated a synergistic effect of varoglutamstat in combination with SGLT-2 inhibitors, suggesting potential for enhanced treatment efficacy [5][11] Strategic Initiatives - Vivoryon plans to initiate a Phase 2b clinical study in diabetic kidney disease (DKD), contingent on additional funding or partnerships [9][21] - The company entered into a Standby Equity Purchase Agreement (SEPA) with Yorkville Advisors for up to EUR 15 million in ordinary shares over the next 36 months, aimed at enhancing financial flexibility [14] Intellectual Property - The company expanded its intellectual property portfolio with a new patent for varoglutamstat, which could provide additional market protection [10][6] Management Updates - Julia Neugebauer was appointed as Chief Operating Officer, overseeing investor relations and corporate functions [20] - CFO Anne Doering will take a temporary leave, with Marcus Irsfeld stepping in as acting CFO [20]

Core Insights - Vivoryon Therapeutics N.V. will report its H1 2025 financial results and operational progress on September 4, 2025 [1] - The company focuses on developing small molecule medicines for inflammatory and fibrotic disorders, particularly kidney diseases [3] Financial Reporting - The financial results will cover the period ended June 30, 2025, and will be available for download on the company's website [1] - A conference call and webcast will be held on the same day to discuss the results [2] Company Overview - Vivoryon is a clinical stage biotechnology company dedicated to innovative treatments for kidney-related inflammatory and fibrotic disorders [3] - The company's leading program, varoglutamstat, is a first-in-class orally available QPCT/L inhibitor aimed at treating diabetic kidney disease [3]

Group 1 - Vivoryon Therapeutics N.V. is a clinical stage biotechnology company focused on developing small molecule medicines for inflammatory and fibrotic disorders, primarily targeting kidney diseases [2][3] - The company will present at two upcoming investor conferences: the mwb online Health Care Conference on July 1, 2025, and the H.C. Wainwright 4th Annual Kidney Virtual Conference on July 14, 2025 [1][2] - The management team attending these conferences includes Frank Weber, CEO, and Julia Neugebauer, COO [1][2] Group 2 - Vivoryon's most advanced program, varoglutamstat, is a proprietary, first-in-class orally available QPCT/L inhibitor being evaluated for the treatment of diabetic kidney disease [2] - The company aims to improve patient outcomes by modulating the activity and stability of pathologically relevant proteins [2]

Core Points - Vivoryon Therapeutics N.V. held its Annual General Meeting (AGM) on June 24, 2025, where shareholders approved all agenda items, including the appointment of Dr. Julia Neugebauer as an executive director [2] - The re-appointment of Dr. Frank Weber and Anne Doering as executive directors, along with the re-appointment of Dr. Erich Platzer, Charlotte Lohmann, Dr. Claudia Riedl, and Dr. Samir Shah as non-executive directors, was also confirmed [2] Company Overview - Vivoryon is a clinical stage biotechnology company focused on developing small molecule medicines for inflammatory and fibrotic disorders, particularly diabetic kidney disease [3] - The company's leading program, varoglutamstat, is a proprietary, first-in-class orally available QPCT/L inhibitor aimed at treating diabetic kidney disease [3]

Core Insights - Vivoryon Therapeutics N.V. reported its Q1 2025 financial results and operational progress, focusing on the development of varoglutamstat for kidney diseases, particularly diabetic kidney disease (DKD) [2][3] Financial Performance - Revenues for Q1 2025 were zero, consistent with Q1 2024 [14] - Research and development expenses decreased by EUR 6.2 million to EUR 1.2 million in Q1 2025 from EUR 7.4 million in Q1 2024, primarily due to lower third-party expenses [14][16] - General and administrative expenses were EUR 1.3 million in Q1 2025, down from EUR 2.1 million in Q1 2024 [16] - Net loss for Q1 2025 was EUR 2.5 million, compared to EUR 9.3 million in Q1 2024 [17] - Cash and cash equivalents as of March 31, 2025, were EUR 7.0 million, down from EUR 9.4 million as of December 31, 2024 [17] Clinical Development - The company is advancing varoglutamstat in kidney disease, with a planned Phase 2b study in DKD as a priority for 2025 [9] - A meta-analysis confirmed that varoglutamstat at 600mg twice daily significantly improved eGFR kidney function, with effects sustained until week 96 [7] - Preclinical data showed a synergistic effect of varoglutamstat in combination with SGLT-2 inhibitors, indicating potential for enhanced treatment regimens [5][6] Intellectual Property - A new composition of matter patent for varoglutamstat was granted in the U.S., providing exclusivity through 2044, with potential extensions [10] - The company is actively pursuing additional patents related to varoglutamstat and its applications in kidney disease [10] Corporate Developments - Vivoryon entered into a Standby Equity Purchase Agreement (SEPA) with Yorkville Advisors for up to EUR 15 million in ordinary shares over the next 36 months, enhancing financial flexibility [12] - Julia Neugebauer was appointed as Chief Operating Officer, effective May 1, 2025, to oversee investor relations and corporate functions [13] Pipeline Updates - The company has nominated a new candidate, VY2149, a next-generation QPCT/L inhibitor, expected to enter late-stage preclinical development [11]

Core Viewpoint - Vivoryon Therapeutics N.V. is set to report its Q1 2025 financial results and operational progress on June 17, 2025, focusing on its development of small molecule medicines for inflammatory and fibrotic disorders, particularly kidney diseases [1][3]. Group 1: Financial Results Announcement - The company will publish its first quarter financial results for the period ended March 31, 2025, on June 17, 2025 [1]. - A corporate update will accompany the financial results announcement [1]. Group 2: Conference Call Details - A conference call will be held on June 17, 2025, at 3:00 pm CEST / 9:00 am EDT, available via phone and webcast [2]. - Participants are encouraged to pre-register for the call to receive dedicated dial-in details and should join 15 minutes early to avoid delays [2]. Group 3: Company Overview - Vivoryon is a clinical stage biotechnology company focused on developing innovative small molecule-based medicines for treating inflammatory and fibrotic disorders of the kidney [3]. - The company's leading program, varoglutamstat, is a first-in-class orally available QPCT/L inhibitor being evaluated for diabetic kidney disease [3].